Vistagen’s US$100 Million Underwritten Offering

Latham & Watkins LLP represents Vistagen in the offering.Vistagen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Marco Zingaro

This content is for Standard 1 Year members only.
Login Join Now